1. Home
  2. PRPL vs INAB Comparison

PRPL vs INAB Comparison

Compare PRPL & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Purple Innovation Inc.

PRPL

Purple Innovation Inc.

SELL

Current Price

$2.27

Market Cap

13.9M

ML Signal

SELL

Logo IN8bio Inc.

INAB

IN8bio Inc.

N/A

Current Price

$1.19

Market Cap

11.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PRPL
INAB
Founded
2010
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Home Furnishings
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.9M
11.8M
IPO Year
2015
2020

Fundamental Metrics

Financial Performance
Metric
PRPL
INAB
Price
$2.27
$1.19
Analyst Decision
Buy
Strong Buy
Analyst Count
3
3
Target Price
★ $20.63
$7.00
AVG Volume (30 Days)
44.1K
★ 45.9K
Earning Date
11-03-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 152.75
N/A
EPS
N/A
★ N/A
Revenue
★ $468,725,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$7.50
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.28
$0.88
52 Week High
$10.00
$2.73

Technical Indicators

Market Signals
Indicator
PRPL
INAB
Relative Strength Index (RSI) 40.77 43.78
Support Level $0.36 $0.92
Resistance Level $10.00 $1.22
Average True Range (ATR) 0.16 0.08
MACD 0.09 -0.02
Stochastic Oscillator 58.49 10.77

Price Performance

Historical Comparison
PRPL
INAB

About PRPL Purple Innovation Inc.

Purple Innovation Inc designs and manufactures sleep products. Using its GelFlex Grid technology, the company designs, manufactures, and offers branded comfort sleep products, including mattresses, pillows, cushions, mattress protectors, bases, sheets, and others. It markets and sells these products through direct-to-consumer e-commerce channels, retail brick-and-mortar wholesale partners, Purple showrooms, and third-party online retailers.

About INAB IN8bio Inc.

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.

Share on Social Networks: